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Abstract
During an area-based study, 75 group B streptococcus (GBS) strains isolated both from early-onset disease (EOD, 37 strains) and from
late-onset disease (LOD, 38 strains) were analysed for serotype, pulsed ﬁeld gel electrophoresis (PFGE) and multilocus sequence typing
proﬁles, protein markers and antibiotic resistance. Serotype III, possessing the rib gene, was the most frequent (54 strains, 72%) and
responsible for 89.5% and 54% of LOD and EOD, respectively. Forty-six serotype III strains belonged to the same PFGE type and clonal
complex 17, already described as an over-represented clone in neonatal invasive GBS infections. Other serotypes were Ia (9.3%), II
(6.7%), Ib (5.3%), V (5.3%) and IV (1.3%). Seventeen PFGE groups were identiﬁed comprising strains with related sequence types; con-
versely, strains displaying the same sequence type could belong to different PFGE groups. When both neonate and maternal strains
from vaginorectal swabs and/or milk were available (eight cases), they were indistinguishable. Resistance to erythromycin (12%) was
associated with a constitutive resistance to clindamycin in ﬁve cases (four carrying the erm(B) gene and one both the erm(B) and mef(E)
genes) and with an inducible clindamycin resistance in two cases (one possessing the erm(A) gene, the other the erm(T) gene). Two iso-
lates displayed the M phenotype (mef(E) gene). All strains but ﬁve were resistant to tetracycline, mostly mediated by the tet(M) gene
(97.1%). The study underlined the importance of an active surveillance system for the elucidation of a GBS population structure causing
neonatal infections and allowed the detection of rare antibiotic resistance determinants [erm(T)].
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Introduction
Group B streptococcus (GBS) is the leading cause of infec-
tious diseases among newborns. Invasive neonatal GBS infec-
tions can present either as an early-onset disease (EOD)
occurring within the ﬁrst week (generally within the ﬁrst
day) and resulting in sepsis and/or pneumonia or as a late-
onset disease (LOD) occurring between 1 week and
3 months of life and accounting for most meningitis cases
and deaths [1].
Since 2002, CDC recommendations for the prevention of
invasive GBS disease in newborns opted for the universal
prenatal culture-based screening for vaginal and rectal GBS
Centre for Disease Control colonization of pregnant women
at 35–37 weeks of gestation, with intrapartum antibiotic pro-
phylaxis (penicillin/ampicillin or macrolide in the case of seri-
ous penicillin allergy) for those with positive cultures [2].
Nevertheless, the observed decline in the incidence of GBS
disease since the adoption of the prevention strategies
related mostly to EOD, with only a slight reduction in LOD
[3].
ª2011 The Authors
Clinical Microbiology and Infection ª2011 European Society of Clinical Microbiology and Infectious Diseases
ORIGINAL ARTICLE INFECTIOUS DISEASES
A total of ten different GBS capsular polysaccharide anti-
genes (Ia, Ib, II–IX) have been described so far; prevalence
studies indicated that EOD is associated with Ia, Ib, II, III and V
serotypes whereas LOD is associated primarily with type III
[4–8]. Other serotypes have been reported mainly in coloniza-
tion studies, with a predominance of serotypes VI and VIII in
Japan and serotype IV in the United Arab Emirates [9,10].
Besides the capsule type, the Alpha-like protein (Alp) fam-
ily, which comprises the surface-localized protein antigens
Alpha-C, Alp1 to 3, and Rib/R4, is commonly used as a GBS
protein marker in epidemiological studies [11].
The analysis of serotypes, protein markers, antibiotic
resistance proﬁles and clonal relationships of invasive neona-
tal GBS strains from an area-based multicentre study is
reported here. This is the ﬁrst time this has been investi-
gated in our country.
Materials and Methods
Bacterial strains and serotyping
From February 2005 to June 2008, 75 non-redundant GBS
strains were isolated from blood and/or cerebrospinal ﬂuid of
infected newborns and infants. In one EOD and seven LOD
cases, neonatal strains were accompanied by isolates from the
maternal vaginorectal swabs collected at the onset of the neo-
natal disease symptoms and, in four LOD cases, from the
maternal milk. In total, 87 GBS strains were analysed.
Bacterial strains were plated on deﬁbrinated sheep blood
agar plates and incubated at 37C in 5% CO2. Identiﬁcation
was conﬁrmed by the Dryspot Streptococcal Grouping Kit
(Oxoid). Serotyping was performed by using both a latex
agglutination test (Statens Serum Institut) and a multiplex
PCR assay [12].
Alpha-like protein (Alp) family
Surface protein markers were inferred by using a multiplex-
PCR for the direct identiﬁcation of the Alp protein genes [13].
Pulsed ﬁeld gel electrophoresis (PFGE) analysis
Total DNA was extracted as previously described [14] and
digested with 40 U of SmaI. Four isolates, all serotype III –
rib, were not DNA-digested by the SmaI enzyme but they
could be resolved by using the XmaI restriction enzyme, a
SmaI isoschizomer. Interpretation of PFGE results and assig-
nation to PFGE group were performed according to the
previously reported criteria [14]. In particular, isolates with
indistinguishable proﬁles were assigned to the same PFGE
type and subtype; isolates with similar proﬁles (differing by
up to ﬁve bands) were considered possibly related and
assigned to different subtypes within the same PFGE type
[15]. Isolates with more than ﬁve bands of difference were
considered unrelated and were identiﬁed as different PFGE
types.
Multilocus sequence typing (MLST) analysis
A subset of 32 isolates from each PFGE type and possessing
different serotype/surface protein combinations were further
genotyped by MLST (http://pubmlst.org/sagalactiae/).
Sequence types (STs) were assigned to one of the previously
described clonal complexes (CCs) included in the GBS MLST
database if they shared ﬁve or more alleles from the most
frequent ST in that CC.
Erythromycin, clindamycin and tetracycline resistance
determinants
Resistance to erythromycin and clindamycin was assessed
phenotypically by both Etest (Biome´riela Italia, Milan, Italy)
for determination of MIC values and the Kirby–Bauer dou-
ble-disk diffusion method to assign the constitutive (CR),
inducible (IR) and M resistant phenotype [16]. The presence
of the macrolide resistance genes erm(A) (subclass erm(TR)),
erm(B) and mef was investigated in a multiplex PCR, as
already described [14]. The mef amplicon was sequenced for
the identiﬁcation of the mef class. PCR conditions and pri-
mer sequences used for ampliﬁcation of the erm(T) gene
were as described [17] and the amplicon was then
sequenced to conﬁrm its identity. Tetracycline resistance
was determined both phenotypically by E-test and genotypi-
cally by studying the occurrence of the resistance genes
tet(M) and tet(O) [18].
Statistical analysis
Fisher’s exact test was used to evaluate the differences in
distribution of isolates. Two-sided p values <0.05 were con-
sidered statistically signiﬁcant (SPSS 17 for Windows).
Results
Clinical features
Among the 37 EOD cases, the most common manifestation
was sepsis (59.4%), followed by septic shock (18.9%) and
bacteraemia (13.5%). Sepsis was deﬁned as GBS bacteraemia
in the presence of clinical signs and symptoms consistent
with a systemic inﬂammatory response. A septic shock was
deﬁned as a sepsis with tachycardia and signs of decreased
perfusion. GBS bacteraemia was conﬁrmed by a blood cul-
ture obtained from a peripheral or umbilical vessel (if <6 h
after catheter insertion) [19].
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Meningitis occurred only in 8.1% of cases of EOD but it
was the prominent clinical condition, together with sepsis in
LOD (42.1% of the cases for each). Other less frequent man-
ifestations observed in LOD were bacteraemia and septic
arthritis (10.5% and 5.3%, respectively).
Invasive GBS infection among preterm infants (gestational
age between 22 and 36 weeks) occurred in 32% of cases (14
EOD and 10 LOD); mortality occurred only in this category
(ﬁve EOD cases, one of which involved a twin birth). The
male:female ratio was 0.88% and 69.3% of infants were Cau-
casian (Table S1).
Serotyping and alpha-like surface protein genes proﬁle
Serotype III strains were the most frequent (54 strains, 72%)
and possessed only the rib gene. Other serotypes were Ia
(seven strains, 9.3%), II (ﬁve strains, 6.7%), V (four strains,
5.3%), Ib (four strains, 5.3%) and IV (one strain, 1.3%). A dif-
ferent distribution of serotypes among EOD and LOD cases
could be noted but only serotype III was signiﬁcantly associ-
ated with LOD (p <0.05) (Table 1 and Table S1).
Early-onset infections were caused by serotype III (20
cases, 54%), serotype Ia (six cases, 16.2%), serotype II (four
cases, 10.8%), serotype V (four cases, 10.8%), serotype Ib
(two cases, 5.4%) and serotype IV (one case, 2.7%). The
spectrum of serotypes responsible for the late-onset disease
was restricted to serotypes III (34 cases, 89.5%), Ib (two
cases, 5.3%), Ia (one case, 2.6%) and II (one case, 2.6%)
(Table 1 and Table S1). The rib gene was the most common
(55 strains, 73.3%) because of its association with serotype
III strains. Only in one case was it present also in serotype
II. The alp1 gene was present in eight strains (10.7%; six
serotypes Ia, one serotype IV and one serotype Ib), the alpha
gene was present in seven strains (9.3%; ﬁve serotype Ib,
two serotype II, one serotype Ia), the alp3 gene was present
only in the three serotype V strains (4%) and the alp2 gene
was detected once in a serotype II strain (1.33%) (Table 1
and Table S1).
PFGE, ST proﬁles and clonal complexes
Analysis of clonal relatedness of the neonatal strains by PFGE
distinguished 17 groups. PFGE patterns that were found to
be superimposable on those already identiﬁed in our previ-
ous study [14] received the same PFGE type designation. In
particular, nine PFGE types (1, 2, 3, 4, 6, 8, 10, 12 and 19)
were previously identiﬁed and eight types (from 36 to 43)
were newly identiﬁed (Table S1). The PFGE groups, encom-
passing at least ﬁve strains, deﬁned group 1 (ﬁve strains of
which three were serotype V, one serotype II and one sero-
type IV), group 2 (six strains of serotype Ia) and group 3 (a
very large cluster comprising 46 strains of serotype III – rib)
(Table S1). The MLST analysis identiﬁed 17 STs, three of
which were newly assigned by the database curator: ST-467
(a single-locus variant of ST-17), ST-420 (a double-locus vari-
ant of ST-17) and ST-449. The sequence types could be
grouped into six clonal complexes, CC17 (49 isolates,
65.3%), CC19 (seven isolates, 9.3%), CC23 (six isolates, 8%),
CC1 (ﬁve isolates, 6.7%), CC12 (ﬁve isolates, 6.7%) and CC7
(one isolate, 1.3%), plus three singletons (ST4, ST22 and
ST449). The PFGE groups included strains displaying the
same ST or belonging to the same clonal complex, while the
same sequence type as for ST-17 and ST-19 or the same clo-
nal complex as for CC17, CC19 and CC12 could be shared
by different PFGE groups (Table 1 and Table S1).
Antibiotic resistance
Resistance to erythromycin was possessed by nine strains
(12%) and was phenotypically associated with a constitutive
resistance to clindamycin in ﬁve cases (four carrying the
erm(B) gene and one carrying both the erm(B) and mef(E)
genes) and with an inducible phenotype in two cases (one
possessing the erm(A) gene and one the erm(T) gene). Nota-
bly, this is the ﬁrst report of the presence of the erm(T)
gene in GBS in our country. Two isolates displayed the M
phenotype carried by the mef(E) gene. All strains but ﬁve
were resistant to tetracycline (93.3%), mediated mainly by
the tet(M) gene (97.1%). Three strains possessed both the
tet(M) and tet(O) gene (Table S1).
Strain identiﬁcation strings and disease manifestation
On the basis of serotype, alp gene, PFGE group and clonal
complex, an identiﬁcation string was assigned to each strain
TABLE 1. Classiﬁcation of the GBS strains responsible for









III rib 3 17 18 28
III rib 6 19 2 1
III rib 37 ST-449 – 1
III rib 38 17 – 2
III rib 39 17 – 1
III rib 42 19 – 1
Ia alp1 2 23 4 1
Ia alpha 2 23 1 –
Ia alp1 36 ST-4 1 –
II alpha 12 12 1 1
II alpha 8 ST-22 1 –
II rib 4 19 1 –
II alp2 1 1 1 –
V alp3 1 1 3 –
V alp1 41 19 1 –
Ib alpha 10 12 1 1
Ib alpha 40 12 – 1
Ib alpha 43 7 1 –
IV alp1 1 1 1 –
Total 37 38
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(Table 1). The clone identiﬁed by the string ‘III, rib, PFGE
type 3, CC-17’ was the most common and responsible for
18 out of the 20 EOD cases (90%) and for 28 out of the 34
LOD cases (82.3%) caused by serotype III.
The string that identiﬁed the single case of LOD caused
by serotype Ia (Ia, alp1, PFGE type 2, CC-23) was prominent
within EOD infections caused by the same serotype. Sero-
type Ib and II strains displayed individual strings, of which
only one, for each serotype, was shared by EOD and LOD
(‘II, alpha, PFGE type 12, CC-12’ and ‘Ib, alpha, PFGE type
10, CC-12’). Serotype V strains were isolated only from
EOD cases and constituted a more homogeneous clone
identiﬁed mainly by the string ‘V, alp3, PFGE type 1, ST-1’.
One EOD case caused by a serotype IV isolate was also
identiﬁed, which is extremely rare in infections in newborns.
The identiﬁcation string ‘IV, alp1, PFGE type 1, ST-196’ indi-
cated that it belonged to the same PFGE group that included
the serotype V strains, all sharing the CC1 (Table S1).
When the neonatal-maternal coupled GBS strains were
available, the typing analysis demonstrated them to be indis-
tinguishable in terms of serotype, surface proteins, PFGE
subtype and MLST typing (Table S1).
Discussion
From February 2005 to June 2008 we received and analysed
75 GBS strains from neonatal invasive infections occurring
in an area where an active surveillance was set up [19–21].
By combining PFGE and MLST analyses we observed a cor-
respondence between PFGE and clonal complex. A total of
17 different PFGE types were identiﬁed among 75 GBS
strains. A total of ﬁve CCs (CC-1, CC-12, CC-17, CC-19
and CC-23) plus one CC-7 strain and three singletons (ST-
4, ST-22 and ST-449) were identiﬁed, with CC-17 account-
ing for 65.3% of all strains. In a previous survey from Italy
including invasive, non-invasive and colonizing GBS strains
mainly from adult patients, four major clonal groups
accounted for 52.7% of all isolates: PFGE type 1/CC1 com-
prising mainly serotype V isolates carrying the alp3 gene,
PFGE type 2/CC23 encompassing serotype Ia isolates with
the alp1 or alpha gene, PFGE type 3/CC17 comprising sero-
type III isolates carrying the rib gene, and PFGE type 4/
CC19 consisting of serotype II and serotype III isolates pos-
sessing the rib gene [14]. The same ‘string associations’
were observed in the present study, indicating a highly clo-
nal GBS population structure. CC-1, CC-12, CC-17, CC-19
and CC-23 are common GBS genetic lineages encountered
in studies dealing with both colonization and disease that,
presumably, resulted from the emergence of host-speciﬁc
clones that successfully spread globally [22]. Nevertheless,
peculiar clone enrichments are represented within adult and
neonatal categories [4,23,24]. It has been hypothesized that
CC-1, along with CC-23, is part of those genotypes more
commonly found in pregnant women, well adapted to the
female genitourinary tract and easily acquired and transmit-
ted to susceptible neonates [23]. Indeed, the serotype dis-
tribution in EOD cases was superimposable on that found
in pregnant women, corroborating the hypothesis of a verti-
cal transmission (R Creti et al., unpublished data). CC-19
seems likely to cause invasive diseases among both neonates
and adults [4,23,25].
In the present study, the clone identiﬁed by the string ‘III,
rib, PFGE type 3, CC-17’ was the most prevalent and
responsible for 18 out of the 20 cases of EOD (90%,
p <0.05) and for 28 out of the 34 cases of LOD (82.3%,
p <0.05). In our previous study, which comprised only 13%
of perinatal infections, strains characterized by the string ‘III,
rib, PFGE type 3, CC17’ were represented to a much lesser
extent (10.6%).
The over-representation of ST-17 among invasive neonatal
strains is recognized worldwide and it is a typical example of
a homogeneous ‘pandemic clone’ with rapid dissemination
and successful adaptation to human neonates [22]. It was
responsible for 15 out of 19 meningitis cases. A very recent
report demonstrated that the propensity of this clone to
cause neonatal meningitis relies on a novel ST-17-speciﬁc
surface-anchored protein (HvgA) that enhances GBS adher-
ence and translocation across the intestinal epithelium and
the blood-brain barrier [26].
One EOD case was caused by a serotype IV GBS. Both of
the patient’s parents were of Caucasian origin. The same
indistinguishable strain was isolated from the mother’s vagi-
norectal swab. This serotype has seldom been found as a
cause of neonatal infections [4,8,27,28] but it predominates
in colonized pregnant women in the United Arab Emirates
and its incidence of carriage is increasing in the US, suggest-
ing that this serotype has the potential to emerge as a neo-
natal pathogen [24].
A total of nine macrolide-resistant GBS strains (12%) were
found. Even if not alarmingly high, this rate stresses the
importance of testing GBS isolates from prenatal screening
for susceptibility to clindamycin and erythromycin, used as a
second choice for intrapartum antibiotic prophylaxis in the
case of patients at high risk for anaphylaxis. All erythromy-
cin-resistant isolates but one exhibited one of the resistance
genotypes studied, with four isolates harbouring the erm(B)
gene, two isolates carrying the mef(E) gene, one isolate
possessing the erm(A) gene, and one isolate carrying both
erm(B) and mef(E) genes. The erythromycin resistance
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prevalence was slightly lower than that observed in our pre-
vious study on GBS strains from different sources of isola-
tion (16.5%), where it was mostly due to serotype V strains
belonging to CC-1 and possessing the erm(B) gene. Serotype
V has emerged recently as a cause of human disease with a
high propensity to acquire macrolide resistance and to
spread throughout the population [8,14,25]. Also, a novel
association between erythromycin resistance and serotype
III/ST-19 has been recently reported [29]. Herein we found
that macrolide resistance was not limited to a speciﬁc sero-
type but was present in four different serotypes, Ia (one iso-
late), Ib (three isolates), III (four isolates) and V (one isolate).
One GBS strain possessed the unusual macrolide resis-
tance determinant erm(T). To date, inducibly clindamycin-
resistant GBS erm(T) gene positive, have been reported only
once [17]. The plasmid-borne erm(T) gene has been previ-
ously detected in erythromycin-resistant animal isolates of
Lactobacillus spp. and human isolates of Streptococcus bovis,
with which GBS shares the same ecological niche, thus sug-
gesting that a lateral gene transfer might occur. Almost all
GBS isolates (93.3%) were resistant to tetracycline, mediated
by the tet(M) gene as already reported [14,25].
While the vertical transmission of GBS from mother to
newborn is clearly involved in the development of EOD, the
mode of LOD transmission is still poorly understood. In the
present study we could observe that when the diseased
newborn’s mother was colonized at the vaginorectal level
and/or her breast milk was positive for GBS, the neonate
and maternal strains were identical; however, no hypothesis
on the routes of transmission could be inferred.
The introduction of a GBS vaccine could have beneﬁts in
preventing GBS-related stillbirths or prematurity (32% of cases
in our study) by providing protection earlier in gestation than
any intrapartum prophylaxis strategy. It would also provide a
longer, more effective, immunity, thus preventing late-onset
GBS infections as well. Finally, an effective vaccine would also
protect the mother against invasive GBS infection [30].
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